CareDx (CDNA) Stock Forecast & Price Target

CareDx is well positioned by its leadership in transplant testing, supported by strong reimbursement, well-documented clinical data, and a broad product suite that now spans kidney, heart, and lung surveillance as well as wrap-around digital and care-management tools. The final CMS transplant LCD removed a major overhang by preserving HeartCare combination testing and allowing for-cause testing while setting coverage limits above current utilization, which should support years of volume growth and improve confidence among medical directors and transplant centers. Fundamental momentum also improved sharply, with Q2’26 revenue of $132M (+52% Y/Y), core test revenue of $100M (+61% Y/Y), 2026 revenue guidance lifted to $490M-$500M, and the Naveris acquisition adding a higher-margin oncology growth engine expected to expand 30%-40% per year.

CareDx is facing a fundamentally challenging outlook because its growth depends heavily on continued adoption and reimbursement of AlloSure Kidney and AlloMap Heart, while clinicians and transplant centers may be slow to change entrenched practices. The company also risks underperforming if it cannot successfully commercialize additional diagnostic solutions, a process that requires substantial R&D, clinical validation, approvals, and years of execution with no guarantee of acceptance. In addition, the July 17, 2025 draft LCD controversy showed how quickly policy risk can pressure sentiment and utilization, with management later quantifying a $15-30 million annualized headwind, or about 4%-8% of revenues.